Sepracor Will Ramp Up Sales Force To Launch NycoMed Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will add 200 reps this year to promote Omnaris and Alvesco, as well as existing products like Lunesta.
You may also be interested in...
Sepracor Plans Alvesco, Omnaris Drug Launches Following Acquisition From Nycomed
Sepracor’s 1,600-person sales force will promote the asthma and allergic rhinitis treatments.
Sepracor Licenses Late-Stage Anti-Epileptic From Portuguese Pharma Bial
Late 2008/early 2009 NDA filing targeted for the new chemical entity as an adjunct therapy to improve control of epileptic seizures.
Nebulized Albuterol Will Not Get NCD Due To Lack Of Data On Patient Subgroups, But Xopenex Loses On Payment Side
Medicare Part B coverage policy for nebulized beta adrenergic agonist therapy for lung disease will continue to be the purview of local Medicare claims contractors.